KLRS
NASDAQ
$4
Kalaris Therapeutics Inc (KLRS)
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. The company is headquartered in Palo Alto, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $18.71 (+367.75%)
Market Cap
$111M
Free Cash Flow Yield
-38.54%
Beta (5Y)
0.81
Price Chart
Valuation
Market Cap$111M
P/B1.59
Profitability
EBITDA-$49M
EPS-$2.15
Financial Health
Free Cash Flow Yield-38.54%
Growth & Risk
EPS 5Y CAGR-39.47%
FCF 5Y CAGR-8.09%
Beta (5Y)0.81
Sharpe Ratio0.96